CGTX CGTX
Company Profile ↓Company Overview
CGTX (CGTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +48.46% |
| 6 Months: | -5.36% |
| 3 Months: | -14.52% |
| 1 Month: | -1.85% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)54.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 66.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -4.46M | -5.58M | -5.98M | -5.22M | -9.41M | -12.21M | -12.62M | -8.97M | -11.82M | -14.74M | -14.10M | -14.68M | -14.46M | -13.78M | -13.98M | -6.38M | -8.82M |
| Net Income | -2.51M | -1.67M | -1.79M | 223.00K | -1.49M | -3.11M | -3.84M | -5.75M | -6.62M | -6.17M | -4.73M | -6.75M | -9.15M | -7.04M | -9.94M | -8.48M | -6.73M | -4.93M | -4.57M |
| Diluted EPS | - | - | -5.31 | -1.64 | -4.77 | -8.12 | -0.17 | -0.25 | -0.29 | -0.21 | -0.16 | -0.22 | -0.27 | -0.18 | -0.25 | -0.14 | -0.11 | -0.06 | -0.05 |
| R&D Expense | - | - | 3.40M | 4.43M | 4.89M | 3.67M | 6.52M | 9.10M | 8.27M | 5.43M | 8.50M | 11.67M | 10.55M | 11.58M | 11.39M | 10.79M | 11.48M | 3.77M | 6.12M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -17.41M | -28.60M | -43.55M | -50.72M | -53.97M | -47.80M |
| Net Income | -7.84M | -11.72M | -21.40M | -25.79M | -33.97M | -23.49M |
| Diluted EPS | -23.76 | -3.13 | -0.91 | -0.86 | -0.86 | -0.32 |
| R&D Expense | 12.89M | 18.57M | 30.32M | 37.20M | 41.68M | 37.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.12M | 59.14M | 50.42M | 35.16M | 30.23M | 48.39M |
| Total Equity | -58.42M | -68.18M | 51.27M | 40.25M | 24.47M | 18.75M | 34.27M |
| Cash & Equivalents | - | 5.19M | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M |
| Total Liabilities | - | 19.93M | 7.86M | 10.18M | 10.69M | 11.48M | 14.12M |
| Current Liabilities | - | 3.25M | 7.86M | 7.79M | 10.17M | 11.14M | 13.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.43M | -3.63M | -18.53M | -16.02M | -28.47M | -24.59M |
| Investing Cash Flow | -10.00K | -27.00K | -171.00K | -147.00K | -4.00K | 9.00K |
| Financing Cash Flow | 5.76M | 53.20M | 5.55M | 4.52M | 23.57M | 36.57M |
| Capital Expenditure | -10.00K | -27.00K | -171.00K | -147.00K | -4.00K | - |
| Free Cash Flow | -3.44M | -3.66M | -18.70M | -16.16M | -28.48M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 11.5% | -22.9% | -53.2% | -105.4% | -181.2% | -68.5% |
| ROCE % | -449.9% | -55.8% | -102.2% | -202.9% | -282.7% | -138.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGTX
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE1PTXMteklnV205YWhzZmE2X185cEJKQW1CVk5pS0dIY2dKdXNIRUxVSk1wdXNLblZGUnZzV1VMTmZzeVItOWtyRHFHWjFmMGxyVTdMeS1IRS05bGs?oc=5" target="_blank">CGTX News | COGNITION THERAPEUTICS INC (NASD…
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdUtBcS1YV25LcVhTTGh3SG5KVWRvTE9HZDVYNzZjcWsyLXVrd0h3b21NNy1xNlhMX19wdDJGYmtJUUdFMTNBSFlqMTg4eEhSN0lPWHZrWXFNMl9oOC1LR25vZFZhRi15WldPZGtxQUFfM056YWk0Tk93UDNsbzlMNVEzTHZDWDVHLW5nM3…
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPbWJ6Mlhya25qVllaa1UwSEI4UjVjSGdqcjFUTnBfR2JwRmlMMURna21vaEszX1FiaGtGc25UNnRjd2dQSWdRUHd3VG96Z1pLWjI5bDdqTmI1NlhCVHJQTHRYYnR2VFhXNTJMOGhCczJjMnBpbnlyRUN2QnN5VmVsNm55ZGpEekNTQ1pPa2…
CGTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9LNGx3MS1kRmtabWhON0ZqTzg3ZHBWNTdocTdYb2NacHdhQW5PakVDeU1KcnJXNmdLRDdxa241WHdtTmlSY1VpTV9iNWJCZE82WXBJeElkeUJaWFZ6ZHVHemRzdFpfZWtTcmFqMy1OTFYxVnlXTjltNjFn?oc=5" target="_blank">CGT…
$CGTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNZjVsYXQ2czNqb0YyelJnb0wxcm0wRENkNmtJbzJCU1Bkb2sxSFBucUdKZVhZZHhPVHpfRFRzMEViTks2OGw2ZGVMbHZsUzlHZ0VBREVrRmt4OHJWNlUyWnc3YTd4czdBUnRGbEtVeDROQWtyT2o1cU5FZEwxYS1SdGQ4cnE1RjhaQWxHQn…
Neuro drug developer to outline DLB psychosis plans at June events - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQTjZocVFqRG5XWDNJYy1aT3FMOTJyellOYjdQazhVWkpjTmJrZE84VW1zdlNNNmZ0SlI1eUgxVUI3bFNyQWNFTWliQkM3OE9MSXlqeVd2VXc3NGtvT1FEMXRtSFNvcWJ4dTRzcWtwd2pYTjhqUURQT1paOG9SdUwtUUh1VnFPbmp3RFNJSG…
CGTX — Frequently Asked Questions
What is the current share price of CGTX?
As of 2026-08-05 17:25 PDT, CGTX trades at $1.06 on NASDAQ/NYSE. Its 52-week range is $0.60 to $3.18.
What is the P/E ratio of CGTX?
CGTX trades at a trailing price-to-earnings (P/E) ratio of -3.31.
What is the return on equity (ROE) of CGTX?
CGTX has a return on equity (ROE) of -68.53%. Its return on capital employed (ROCE) is -138.68%.
Is CGTX a good stock to buy?
This page provides a data-driven analysis of CGTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.